Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia

OBJECTIVE: The aim of this study was to investigate the anti-leukemic activity of the Bruton tyrosine kinase inhibitor Ibrutinib in combination with the small molecule MDM-2 inhibitor Nutlin-3 in preclinical models. METHODS: The potential efficacy of the Ibrutinib/Nutlin-3 combination was evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Voltan, Rebecca, Rimondi, Erika, Melloni, Elisabetta, Rigolin, Gian Matteo, Casciano, Fabio, Arcidiacono, Maria Vittoria, Celeghini, Claudio, Cuneo, Antonio, Zauli, Giorgio, Secchiero, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342579/
https://www.ncbi.nlm.nih.gov/pubmed/27661115
http://dx.doi.org/10.18632/oncotarget.12139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342579/
https://www.ncbi.nlm.nih.gov/pubmed/27661115
http://dx.doi.org/10.18632/oncotarget.12139

Ejemplares similares